Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

A mix of tolerable benefit cuts and realistic revenue increases would make everyone better off In early January, Stephen Goss, Social Security's chief actuary released estimates of a comprehensive ...

Wall Street is coming off a losing session after the Federal Reserve paused its interest rate-cutting campaign, leaving its ...

If you take a GLP-1 medication, like Ozempic, Wegovy, Mounjaro, or Zepbound, you may want to take a look at your diet. These weight loss drugs are hailed for their ability to slow down digestion and ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation in pain relief in more than two decades.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...